These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 36060450)
41. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: What are the differences? Vroomen LGPH; Petre EN; Cornelis FH; Solomon SB; Srimathveeravalli G Diagn Interv Imaging; 2017 Sep; 98(9):609-617. PubMed ID: 28869200 [TBL] [Abstract][Full Text] [Related]
42. Imaging considerations for thermal and radiotherapy ablation of primary and metastatic renal cell carcinoma. Haroon M; Sathiadoss P; Hibbert RM; Jeyaraj SK; Lim C; Schieda N Abdom Radiol (NY); 2021 Nov; 46(11):5386-5407. PubMed ID: 34245341 [TBL] [Abstract][Full Text] [Related]
43. The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes. Koza A; Bhogal RH; Fotiadis N; Mavroeidis VK Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189680 [TBL] [Abstract][Full Text] [Related]
45. Alternative to surgery in early stage NSCLC-interventional radiologic approaches. Lee KS; Pua BB Transl Lung Cancer Res; 2013 Oct; 2(5):340-53. PubMed ID: 25806253 [TBL] [Abstract][Full Text] [Related]
50. Advanced Pancreatic Cancer: High-Intensity Focused Ultrasound (HIFU) and Other Local Ablative Therapies. Marinova M; Wilhelm-Buchstab T; Strunk H Rofo; 2019 Mar; 191(3):216-227. PubMed ID: 30703824 [TBL] [Abstract][Full Text] [Related]
51. The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma. Barbour AB; Kirste S; Grosu AL; Siva S; Louie AV; Onishi H; Swaminath A; Teh BS; Psutka SP; Weg ES; Chen JJ; Zeng J; Gore JL; Hall E; Liao JJ; Correa RJM; Lo SS Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509333 [TBL] [Abstract][Full Text] [Related]
52. Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation. Kwak K; Yu B; Lewandowski RJ; Kim DH Theranostics; 2022; 12(5):2175-2204. PubMed ID: 35265206 [TBL] [Abstract][Full Text] [Related]
53. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC Eur Urol; 2015 Feb; 67(2):252-9. PubMed ID: 25108580 [TBL] [Abstract][Full Text] [Related]
54. Treatment options for localised renal cell carcinoma of the transplanted kidney. Motta G; Ferraresso M; Lamperti L; Di Paolo D; Raison N; Perego M; Favi E World J Transplant; 2020 Jun; 10(6):147-161. PubMed ID: 32742948 [TBL] [Abstract][Full Text] [Related]
55. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Heuer R; Gill IS; Guazzoni G; Kirkali Z; Marberger M; Richie JP; de la Rosette JJ Eur Urol; 2010 Feb; 57(2):223-32. PubMed ID: 19853989 [TBL] [Abstract][Full Text] [Related]
56. Percutaneous Image-Guided Thermal Ablation for Multifocal Renal Cell Carcinoma: 10-Year Experience at a Single Center. Zhou W; Uppot RN; Feldman AS; Arellano RS AJR Am J Roentgenol; 2017 Oct; 209(4):733-739. PubMed ID: 28678572 [TBL] [Abstract][Full Text] [Related]
57. Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer. Ito K; Soga S; Seguchi K; Shinchi Y; Masunaga A; Tasaki S; Kuroda K; Sato A; Asakuma J; Horiguchi A; Shinmoto H; Kaji T; Asano T Oncol Lett; 2017 Jul; 14(1):918-924. PubMed ID: 28693252 [TBL] [Abstract][Full Text] [Related]
59. Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype. Liu N; Huang D; Cheng X; Chong Y; Wang W; Gan W; Guo H Urol Oncol; 2017 Aug; 35(8):530.e1-530.e6. PubMed ID: 28408296 [TBL] [Abstract][Full Text] [Related]